Dr. Jeffrey Jones on the Efficacy of Venetoclax in Treatment for CLL
Jeffrey Jones, MD, discusses small molecule inhibitors of B-cell receptor signaling in chronic lymphocytic leukemia (CLL).
Jeffrey Jones, MD, assistant professor of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses small molecule inhibitors of B-cell receptor signaling in chronic lymphocytic leukemia (CLL). Jones says both idelalisib and ibrutinib have been highly effective in the majority of relapsed/refractory CLL.
Jones says that while idelalisib and ibrutinib have been effective overall, there is a small group of patients who cannot receieve the treatment. He says that a different option for patients who cannot undergo those treatments are BCL-2 inhibitors like venetoclax. He adds that in a recent study, venetoclax has proven to be effective in the patient population with CLL who cannot receieve idelalisib and ibrutinib due to toxiticies or high-risk genetic features.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
